2.2.0.7 false Acquisition of Gloucester Pharmaceuticals Inc. (Policies) 0403 - Disclosure - Acquisition of Gloucester Pharmaceuticals Inc. (Policies) true false false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 $ 2 Acquisition of Gloucester Pharmaceuticals Inc. (Policies) [Abstract] 0 celg_AcquisitionOfGloucesterPharmaceuticalsIncPoliciesAbstract celg false na duration Acquisition of Gloucester Pharmaceuticals Inc Policies Abstract. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string Acquisition of Gloucester Pharmaceuticals Inc Policies Abstract. false 3 ASC No.805, Business Combinations 1 us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0   <div align="justify" style="font-size: 10pt; font-family: 'Times New Roman',Times,serif"> <div align="justify" style="font-size: 10pt; margin-top: 10pt">On January 15, 2010, the Company acquired all of the outstanding common stock and stock options of Gloucester in a transaction accounted for under the acquisition method of accounting for business combinations, ASC No. 805, “Business Combinations,” or ASC 805. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Gloucester were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The reported consolidated financial condition and results of operations of the Company after completion of the acquisition reflect these fair values. Gloucester’s results of operations are included in the Company’s consolidated financial statements from the date of acquisition. Gloucester’s results of operations prior to the acquisition were determined to be immaterial to the Company; therefore, proforma financial statements are not required to be presented. </div> </div>    <div align="justify" style="font-size: 10pt; font-family: 'Times New Roman',Times,serif"> <div align="justify" style="font-size: 10pt; margin-top: 10pt">The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. The Company does not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to the Company’s acquisition of Gloucester has been recorded as a noncurrent asset in its Consolidated Balance Sheets and is not amortized, but is subject to review for impairment in accordance with ASC 350, “Goodwill and Other Intangible Assets.” </div> </div>  <!-- Begin Block Tagged false false false us-types:textBlockItemType textblock Describes an entity's accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7-18, 22 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 4, 11-23, 26, 34 false 1 3 false UnKnown UnKnown UnKnown false true